Clinical Context
A typical patient receiving J2356 (tezepelumab-ekko, 1 mg) is an adult or adolescent with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus another controller and, often, previous biologic therapy. The clinical workflow begins with specialist evaluation in an outpatient allergy/immunology or pulmonology clinic. The patient presents with persistent symptoms (daily wheeze, frequent exacerbations, reduced lung function) and objective evidence of type 2 inflammation may be present but is not required for tezepelumab-ekko use.
After confirmation of eligibility and documented prior therapy failures, baseline assessments are obtained: spirometry, exacerbation history, current medications, and relevant labs. The drug is supplied as a prefilled syringe or single-use vial; the ordered dose is converted to milligrams and billed as units of J2356 (1 mg per unit). Administration is typically by subcutaneous injection in the clinic by a licensed nurse. Observation for immediate adverse reactions follows per facility protocol (commonly 15–30 minutes). Dosing occurs every 4 weeks after an initial loading schedule per product labeling. Documentation includes indication, dose in mg and units billed, lot number, route (subcutaneous), site, patient consent, and any observation findings.
Typical site of service is an outpatient infusion or injection clinic, physician office, or ambulatory care setting. Pharmacy dispensing and storage documentation is maintained per provider and payer rules. Billing often pairs J2356 with appropriate visit codes and, when applicable, injection administration CPT codes or facility revenue codes; clinical documentation supports medical necessity for severe asthma management.